| Symbol | CMND |
|---|---|
| Name | CLEARMIND MEDICINE INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | Canada |
| Telephone | 972-54-5704749 |
| Fax | — |
| — | |
| Website | https://www.clearmindmedicine.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001892500 |
| Description | Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The companys intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Additional info from NASDAQ: |
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
Read moreNew Form F-3 - Clearmind Medicine Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001213900-26-050265 <b>Size:</b> 505 KB
Read moreClearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Read moreClearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
Read moreClearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05913752 | A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Su… | Phase1 | Alcohol Use Disorder | Recruiting | 2025-04-30 | 2026-12-31 | ClinicalTrials.gov |
| NCT04839770 | MIECH: The Minimally Invasive Endoscopic Surgery With the Axonpen System for Sp… | Na | Intracerebral Hemorrhage | Completed | 2020-08-07 | 2023-01-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Axonpen system | Other | Approved | Intracerebral Hemorrhage | COMPLETED | NCT04839770 |
| Axonpen system | Other | Approved | Intracerebral Hemorrhage | COMPLETED | NCT04839770 |
| CMND-100 | Other | Phase PHASE1 | Alcohol Use Disorder | RECRUITING | NCT05913752 |
| Axonpen system | DEVICE | Approved | Intracerebral Hemorrhage | COMPLETED | NCT04839770 |
| CMND-100 | DRUG | Phase PHASE1 | Alcohol Use Disorder | RECRUITING | NCT05913752 |